Residual renal function after partial or radical nephrectomy for renal cell carcinoma

Journal of the Canadian Urological Association

Volumn 4, Issue 5, 2010, Pages 337-343

  Chapman, David ^a   Moore, Ron ^a   Klarenbach, Scott ^a   Braam, Branko ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957732771     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Setiawan VW, Stram DO, Nomura AM, et al. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 2007;166:932-940.
2. Coleman JA. Familial and hereditary renal cancer syndromes. Urol Clin North Am 2008;35:563-572.
3. Karakiewicz PI, Jeldres C, Suardi N, et al. Age at diagnosis is a determinant factor of renal cell carcinomaspecific survival in patients treated with nephrectomy. Can Urol Assoc J 2008;2:610-617.
4. Bergstrom A, Hsieh CC, Lindblad P, et al. Obesity and renal cell cancer--a quantitative review. Br J Cancer 2001;85:984-990.
5. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-429.
6. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
7. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009;20:2305-2313.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266.
9. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
10. Nguyen CT, Campbell SC, Novick AC. Choice of operation for clinically localized renal tumour. Urol Clin North Am 2008;35:645-655.
11. Bensalah K, Crepel M, Patard JJ. Tumour size and nephron-sparing surgery: does it still matter? Eur Urol 2008;53:691-693.
12. Heuer R, Gill IS, Guazzoni G, et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol 2010;57:223-232.
13. Simmons M N, Weight CJ, Gill IS. Laparoscopic radical versus partial nephrectomy for tumours >4 cm: intermediate-term oncologic and functional outcomes. Urology 2009;73:1077-1082.
14. Crepel M, Jeldres C, Perrotte P, et al. Nephron-sparing Surgery Is Equally Effective to Radical Nephrectomy for T1BN0M0 Renal Cell Carcinoma: A Population-Based Assessment. Urology Epub 2009 Dec 4.
15. Russo P, Huang W. The medical and oncological rationale for partial nephrectomy for the treatment of T1 renal cortical tumours. Urol Clin North Am 2008;35:635-643.
16. Lebed B, Jani SD, Kutikov A, et al. Renal Masses Herniating Into the Hilum: Technical Considerations of the "Ball-valve Phenomenon" During Nephron-sparing Surgery. Urology Epub 2009 Oct 24.
17. Bijol V, Mendez GP, Hurwitz S, et al. Evaluation of the nonneoplastic pathology in tumour nephrectomy specimens: predicting the risk of progressive renal failure. Am J Surg Pathol 2006;30:575-584.
18. Ross LF, Thistlethwaite JR Jr. Long-term consequences of kidney donation. N Engl J Med 2009;360:2371; author reply 2372.
19. Kane CJ, Mitchell JA, Meng MV, et al. Laparoscopic partial nephrectomy with temporary arterial occlusion: description of technique and renal functional outcomes. Urology 2004;63:241-246.
20. Bakirtas H, Eroglu M, Naldoken S, et al. Nephron-sparing surgery: the effect of surface cooling and temporary renal artery occlusion on renal function. Urol Int 2009;82:24-27.
21. Kondo T, Nakazawa H, Ito F, et al. Impact of arterial occlusion during partial nephrectomy on residual renal function: an evaluation with (99m)technetium-dimercaptosuccinic acid scintigraphy. Int J Urol 2002;9:435-440.
22. Shirasaki Y, Tsushima T, Saika T, et al. Kidney function after nephrectomy for renal cell carcinoma. Urology 2004;64:43-47.
23. Donckerwolcke RM, Coppes MJ. Adaptation of renal function after unilateral nephrectomy in children with renal tumours. Pediatr Nephrol 2001;16:568-574.
24. Carmines PK, Fleming JT. Control of the renal microvasculature by vasoactive peptides. FASEB J 1990;4:3300-3309.
25. Denton KM, Luff SE, Shweta A, et al. Differential neural control of glomerular ultrafiltration. Clin Exp Pharmacol Physiol 2004;31:380-386.
26. Komlosi P, Bell PD, Zhang ZR. Tubuloglomerular feedback mechanisms in nephron segments beyond the macula densa. Curr Opin Nephrol Hypertens 2009;18:57-62.
27. Kasinath BS, Feliers D, Sataranatarajan K, et al. Regulation of mRNA translation in renal physiology and disease. Am J Physiol Renal Physiol 2009 Epub 2009 Jun 17.
28. Hayslett JP. Functional adaptation to reduction in renal mass. Physiol Rev 1979;59:137-164.
29. Katz AI, Epstein FH. Relation of glomerular filtration rate and sodium reabsorption to kidney size in compensatory renal hypertrophy. Yale J Biol Med 1967;40:222-230.
30. Levine DZ, Iacovitti M, Robertson SJ. Modulation of single-nephron GFR in the db/db mouse model of type 2 diabetes mellitus. II. Effects of renal mass reduction. Am J Physiol Regul Integr Comp Physiol 2008;294:R1840-R1846.
31. Westenend PJ, Nooyen YA, van der Krogt JA, et al. Functional and structural determinants of glomerulosclerosis in the fawn-hooded rat. Eur J Clin Invest 1992;22:391-395.
32. Kasiske BL, O'Donnell MP, Cleary MP, et al. Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. Kidney Int 1989;35:40-47.
33. Bieniasz M, Domagala P, Kwiatkowski A, et al. The assessment of residual kidney function after living donor nephrectomy. Transplant Proc 2009;41:91-92.
34. Wilton P, Aperia A, Broberger O, et al. Renal compensatory hypertrophy in children with unilateral renal disease. Acta Paediatr Scand 1980;69:83-88.
35. Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 2010;303:959-966.
36. Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med 2009;360:459-469.
37. Garg AX, Muirhead N, Knoll G, et al. Proteinuria and reduced kidney function in living kidney donors: A systematic review, meta-analysis, and meta-regression. Kidney Int 2006;70:1801-1810.
38. Boudville N, Prasad GV, Knoll G, et al. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med 2006;145:185-196.
39. Siemer S, Lehmann J, Loch A, et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 2005;173:33-37.
40. Ares Valdes Y. Correlation between symptoms and survival in patients with renal cell carcinoma [in Spanish]. Arch Esp Urol 2009;62:201-206.
41. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735-740.
42. Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008;179:468-471.
43. Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75:1236-1242.
44. Polascik TJ, Pound CR, Meng MV, et al. Partial nephrectomy: technique, complications and pathological findings. J Urol 1995;154:1312-1318.
45. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
46. Reeves DJ, Liu CY. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2009;64:11-25.
47. Saylor PJ, Michaelson MD. New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw 2009;7:645-656.
48. Radulovic S, Bjelogrlic SK. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON 2007;12(Suppl 1):S151-S62.
49. Merseburger AS, Waalkes S, Kuczyk MA. Current state of systemic therapy of metastatic renal cell carcinoma [in German] Urologe A 2009;48:986, 988-989.
50. Braam B. Renal endothelial and macula densa NOS: integrated response to changes in extracellular fluid volume. Am J Physiol 1999;276:R1551-R1561.
51. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-1144.
52. Theou-Anton N, Faivre S, Dreyer C, et al. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. Drug Saf 2009;32:717-734.
53. Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12:7271-7278.
54. Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care 2009;3:170-179.
55. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48:9-17.
56. Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009;24:682-685.
57. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-962.
58. Jaar BG, Coresh J, Plantinga LC, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005;143:174-183.